AstraZeneca's Tagrisso just got the lung cancer nod it needs to hit $3B in sales
admin 19th April 2018 Uncategorised 0The future may still be uncertain for AstraZeneca’s immuno-oncology therapy Imfinzi in first-line lung cancer. But the company has picked up an approval in that setting for fellow portfolio med Tagrisso, which targets tumors with a particular genetic mutation.
More: AstraZeneca's Tagrisso just got the lung cancer nod it needs to hit B in sales
Source: fierce